Keywords: good, ph, ii, interim, data, vernalis, frova

Good Ph II interim data on Vernalis' Frova

Article | 04 July 2005

UK drugmaker Vernalis has reported six-month interim safety data for frovatriptan, its candidate drug for the prevention of menstrually-related migraine, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Endo Pharmaceuticals

Go to company listing

Related Drugs

Frova

Frovatriptan Succinate

Go to drug listing